| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -63,316 | -17,666 | -3,355 |
| Depreciation and amortization expense | 6,809 | 6,881 | 18,343 |
| Stock-based compensation expense | 8,996 | 9,780 | 22,382 |
| Change in fair value of financial liabilities | -2,540 | -1,116 | 2,320 |
| Deferred tax expense | 449 | NaN | 448 |
| Provision for excess and obsolete inventory | NaN | -17 | 152 |
| Legal reserves | NaN | -4,750 | -810 |
| Change in third party payor reserves | -1,022 | 6,297 | -8,746 |
| Loss on extinguishment of debt | -6,565 | NaN | NaN |
| Impairment loss | 31,287 | 0 | NaN |
| Other | 1,034 | 781 | 2,382 |
| Accounts receivable | 2,558 | 13,432 | 22,799 |
| Inventory | -1,689 | 3,364 | 72 |
| Accounts payable and accrued expenses | -13,168 | 6,915 | 5,185 |
| Other assets and liabilities | 9,125 | -10,143 | -1,827 |
| Net cash (used in) provided by operating activities | -32,408 | -3,090 | 36,369 |
| Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Series Of Individually Immaterial Business Acquisitions | NaN | 32,856 | NaN |
| Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Gene Dx | NaN | 0 | NaN |
| Purchases of marketable securities | 20,177 | 19,141 | 36,535 |
| Proceeds from sales of marketable securities | 875 | 2,062 | 0 |
| Acquisition of business, net of cash acquired | NaN | NaN | 33,195 |
| Proceeds from maturities of marketable securities | 8,500 | 10,015 | 33,955 |
| Purchases of property and equipment and development of internal-use software | 6,453 | 4,347 | 14,670 |
| Proceeds from sales of assets | NaN | 0 | NaN |
| Development of internal-use software assets | NaN | 0 | NaN |
| Net cash used in investing activities | -17,255 | -11,072 | -50,445 |
| Proceeds from long term debt, net of issuance costs | 96,998 | 21,136 | 25,568 |
| Proceeds from issuance of stock pursuant to employee stock purchase plan | NaN | 1,699 | 1,262 |
| Proceeds from issuance of common stock from subscription agreements | 476 | NaN | NaN |
| Exercise of stock options | 58 | 1,040 | 982 |
| Repayment and principal payments for long-term debt-Perceptive Term Loan Facility | 54,000 | NaN | NaN |
| Long-term debt principal payments | NaN | 305 | 906 |
| Repayment and principal payments for long-term debt-DECDLoan Agreement | 4,447 | NaN | NaN |
| Finance lease principal payments | 495 | 377 | 2,074 |
| Proceeds from long-term debt | NaN | 0 | NaN |
| Net cash provided by financing activities | 38,590 | 23,193 | 24,832 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -11,073 | 9,031 | 10,756 |
| Cash, cash equivalents and restricted cash, at beginning of period | 105,989 | 96,958 | 86,202 |
| Cash, cash equivalents and restricted cash, at end of period | 94,916 | 105,989 | 96,958 |
GeneDx Holdings Corp. (WGSWW)
GeneDx Holdings Corp. (WGSWW)